Preventive effect of argatroban on ellagic acid-induced cerebral thromboembolism in rats
| Autor: | Munehiro Tomikawa, Tsuyoshi Hara, Masahiro Iwamoto, Masanao Ishihara |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Male
medicine.drug_class Cerebral arteries Pharmacology Arginine Argatroban Fibrin Brain Ischemia chemistry.chemical_compound Thrombin Ellagic Acid Physiology (medical) medicine Animals Sulfonamides biology business.industry Cerebral infarction Heparin Anticoagulant Hematology Cerebral Infarction Intracranial Embolism and Thrombosis medicine.disease Rats Survival Rate Disease Models Animal chemistry Spectrophotometry Anesthesia Pipecolic Acids Injections Intravenous biology.protein business medicine.drug Ellagic acid |
| Zdroj: | Haemostasis. 24(6) |
| ISSN: | 0301-0147 |
| Popis: | The preventive effect of argatroban, a synthetic thrombin inhibitor, on cerebral infarction was evaluated with ellagic acid (EA)-induced cerebral thromboembolism in rats. Platelet-rich thrombi containing fibrin and EA crystal were formed in the microarteries in the affected hemisphere by the injection of EA suspension into the cerebral arteries. The mortality in saline control was over 80% 6 h after the EA injection. Argatroban decreased the mortality to 0% at a dose of 3 mg/kg/h, and significantly reduced the ischemic area in the affected cerebral hemisphere. Heparin also decreased the mortality to 30% at a dose of 600 U/kg/h, but marked bleeding was observed at the incised wound. These findings suggest that argatroban is a more effective and safer anticoagulant than heparin for the prevention of ischemic damage on cerebral thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|